Solstice
It builds AI-native marketing software for pharmaceutical companies to accelerate drug campaign development from months to days.
Overview
Solstice is an AI-native pharma marketing startup focused on shortening the time required to build drug campaigns. Its offering targets pharmaceutical commercial and marketing teams seeking to move campaign development from traditional multi-month timelines to faster AI-assisted workflows. The company’s stated differentiator is speed: it aims to cut drug campaign timelines from about three months to 10 days. Solstice raised $21 million in an undisclosed round announced in May 2026, bringing total disclosed funding to $21 million.
Funding History
AI-native pharma marketing startup Solstice raises $21M to cut drug campaign timelines from 3 months to 10 days
Frequently Asked Questions
- How much funding does AI Funding track for Solstice?
- AI Funding tracks $21M for Solstice across 1 funding round in this database.
- Who are Solstice's investors?
- Solstice's investors include Transformation Capital, Twelve Below, Virtue Ventures.
- What does Solstice do?
- Solstice is an AI-native pharma marketing startup focused on shortening the time required to build drug campaigns. Its offering targets pharmaceutical commercial and marketing teams seeking to move campaign development from traditional multi-month timelines to faster AI-assisted workflows. The company’s stated differentiator is speed: it aims to cut drug campaign timelines from about three months to 10 days. Solstice raised $21 million in an undisclosed round announced in May 2026, bringing total disclosed funding to $21 million.
- Where is Solstice headquartered?
- Solstice is headquartered in San Francisco, CA.
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.